Insmed, Inc. $INSM Shares Sold by Axiom Investors LLC DE

Key Points

• Axiom Investors LLC DE reduced its stake in Insmed, Inc. by 4.7%, holding 79,925 shares valued at approximately $6.10 million.
• Several institutional investors, including Deutsche Bank AG and Cetera Investment Advisers, significantly increased their holdings in Insmed during the fourth quarter.
• Analysts have a consensus "Moderate Buy" rating for Insmed, with target prices raised to as high as $148.00 by Jefferies Financial Group.

Axiom Investors LLC DE cut its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 4.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,925 shares of the biopharmaceutical company's stock after selling 3,949 shares during the quarter. Axiom Investors LLC DE's holdings in Insmed were worth $6,097,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Cullen Frost Bankers Inc. grew its position in shares of Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 221 shares during the last quarter. Elequin Capital LP acquired a new stake in shares of Insmed in the fourth quarter valued at approximately $28,000. NBC Securities Inc. acquired a new stake in shares of Insmed in the first quarter valued at approximately $49,000. Versant Capital Management Inc grew its position in shares of Insmed by 546.3% in the first quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 590 shares during the last quarter. Finally, Signaturefd LLC grew its position in shares of Insmed by 60.0% in the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock valued at $66,000 after purchasing an additional 325 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on INSM shares. HC Wainwright upped their price objective on shares of Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. Mizuho upped their price objective on shares of Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a research note on Wednesday, August 13th. Wells Fargo & Company upped their price objective on shares of Insmed from $140.00 to $171.00 and gave the company an "overweight" rating in a research note on Wednesday, September 3rd. JPMorgan Chase & Co. upped their price objective on shares of Insmed from $111.00 to $135.00 and gave the company an "overweight" rating in a research note on Wednesday, August 20th. Finally, Citigroup raised shares of Insmed to a "buy" rating in a research note on Tuesday, June 10th. Sixteen research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $139.86.

Insider Buying and Selling at Insmed

In related news, CFO Sara Bonstein sold 58,400 shares of the firm's stock in a transaction on Monday, July 21st. The shares were sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the completion of the sale, the chief financial officer directly owned 73,505 shares of the company's stock, valued at approximately $7,546,758.35. This trade represents a 44.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO William Lewis sold 6,865 shares of the firm's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $128.40, for a total transaction of $881,466.00. Following the sale, the chief executive officer directly owned 233,924 shares of the company's stock, valued at approximately $30,035,841.60. The trade was a 2.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 378,382 shares of company stock worth $40,169,038. 3.00% of the stock is currently owned by insiders.

Insmed Trading Up 0.1%

Shares of Insmed stock traded up $0.14 during trading hours on Friday, hitting $145.93. The company's stock had a trading volume of 1,925,973 shares, compared to its average volume of 2,769,656. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $149.08. The business has a fifty day moving average of $118.45 and a 200 day moving average of $91.43. The company has a market capitalization of $30.85 billion, a PE ratio of -25.56 and a beta of 0.97. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same period in the previous year, the company earned ($1.94) EPS. Insmed's revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.